These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 1597205)

  • 41. [In vitro activity of 4 fluoroquinolones against Klebsiella pneumoniae. Distribution according to phenotype resistance to aminoglycosides or beta-lactams].
    Miguères ML; Ronco E; Guenounou M
    Pathol Biol (Paris); 1990 May; 38(5):385-9. PubMed ID: 2195447
    [TBL] [Abstract][Full Text] [Related]  

  • 42. In vitro activity of enoxacin versus ciprofloxacin, fleroxacin, lomefloxacin, ofloxacin, pefloxacin, and rufloxacin against uropathogens.
    Naber KG; Well M; Hollauer K; Kirchbauer D; Witte W
    Chemotherapy; 1998; 44(2):77-84. PubMed ID: 9551236
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Combination therapy: a way to limit emergence of resistance?
    Michéa-Hamzehpour M; Pechère JC; Marchou B; Auckenthaler R
    Am J Med; 1986 Jun; 80(6B):138-42. PubMed ID: 3088999
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Activity of cefotaxime and ceftriaxone and of imipenem, pefloxacin and norfloxacin on 13 species of bacteria].
    Rahal K
    Arch Inst Pasteur Alger; 1989; 57():213-48. PubMed ID: 2489401
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Evaluation of bacterial resistance to pefloxacine after prolonged use in resuscitation].
    Malacarne P; Casagli S; Kaisserli P
    Minerva Anestesiol; 1992; 58(1-2):1-5. PubMed ID: 1589059
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Kinetics of endotoxin release by gram-negative bacteria in the intestinal tract of mice during oral administration of bacitracin and during in vitro growth.
    Goris H; de Boer F; van der Waaij D
    Scand J Infect Dis; 1988; 20(2):213-9. PubMed ID: 2969614
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Antimicrobial activity of pefloxacin in comparison with other quinolones].
    Darenkov AF; Kotliarova GA; Kondrat'eva EM
    Antibiot Khimioter; 1991 Nov; 36(11):24-6. PubMed ID: 1793290
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Biphasic kinetics of bacterial killing by quinolones.
    Carret G; Flandrois JP; Lobry JR
    J Antimicrob Chemother; 1991 Mar; 27(3):319-27. PubMed ID: 2037537
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The effect of cefuroxime axetil on the faecal flora of healthy volunteers.
    Leigh DA; Walsh B; Leung A; Tait S; Peatey K; Hancock P
    J Antimicrob Chemother; 1990 Aug; 26(2):261-8. PubMed ID: 2211457
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Overgrowth of Enterococcus faecium in the feces of patients with hematologic malignancies.
    Suppola JP; Volin L; Valtonen VV; Vaara M
    Clin Infect Dis; 1996 Oct; 23(4):694-7. PubMed ID: 8909828
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Antimicrobial properties of natural coniferous rosin in the European Pharmacopoeia challenge test.
    Sipponen A; Laitinen K
    APMIS; 2011 Oct; 119(10):720-4. PubMed ID: 21917009
    [TBL] [Abstract][Full Text] [Related]  

  • 52. TLR-7 activation enhances IL-22-mediated colonization resistance against vancomycin-resistant enterococcus.
    Abt MC; Buffie CG; Sušac B; Becattini S; Carter RA; Leiner I; Keith JW; Artis D; Osborne LC; Pamer EG
    Sci Transl Med; 2016 Feb; 8(327):327ra25. PubMed ID: 26912904
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Influence of a new fluoroquinolone, AF3013 (the active metabolite of prulifloxacin), on macrophage functions against Klebsiella pneumoniae: an in vitro comparison with pefloxacin.
    Tullio V; Cuffini AM; Bonino A; Palarchio AI; Roana J; Mandras N; Rossi V; Carlone NA
    J Antimicrob Chemother; 2000 Aug; 46(2):241-7. PubMed ID: 10933647
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The influence of quinolones on the faecal flora.
    Midtvedt T
    Scand J Infect Dis Suppl; 1990; 68():14-8. PubMed ID: 2218416
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Antimicrobial resistance surveillance of bacteria in 1999 in Korea with a special reference to resistance of enterococci to vancomycin and gram-negative bacilli to third generation cephalosporin, imipenem, and fluoroquinolone.
    Lee K; Lee HS; Jang SJ; Park AJ; Lee MH; Song WK; Chong Y;
    J Korean Med Sci; 2001 Jun; 16(3):262-70. PubMed ID: 11447969
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Evaluation of the effects of pefloxacin on platelet aggregation in vitro and ex vivo in patients suffering from chronic bronchitis.
    Cazzola M; Santangelo G; Angrisani M; Vinciguerra A; Contaldi C; Rossi F
    J Chemother; 1995 Feb; 7(1):38-41. PubMed ID: 7629557
    [TBL] [Abstract][Full Text] [Related]  

  • 57. In vitro antibacterial activity of trovafloxacin and five other fluoroquinolones.
    Montanari MP; Prenna M; Mingoia M; Ripa S; Varaldo PE
    Chemotherapy; 1998; 44(2):85-93. PubMed ID: 9551237
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Meropenem use and colonization by antibiotic-resistant Gram-negative bacilli in a pediatric intensive care unit.
    Toltzis P; Dul M; O'Riordan MA; Melnick D; Lo M; Blumer J
    Pediatr Crit Care Med; 2009 Jan; 10(1):49-54. PubMed ID: 19057450
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Emergence of resistance to fluoroquinolones among gram positive and gram negative clinical isolates.
    Nesar S; Shoaib MH; Rahim N; Rehman R
    Pak J Pharm Sci; 2012 Oct; 25(4):877-81. PubMed ID: 23010009
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Multiple-resistant enterococci and gram-negative bacteria: tracking gene dissemination.
    Struelens MJ
    Microb Drug Resist; 1995; 1(3):193-4. PubMed ID: 9158774
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.